Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Financial Results · Q3 2026

Innoviva Q3 2026 Results: Net Loss of $73.9M

Innoviva, Inc. reported total revenue of $323.7 million for the nine months ended September 30, 2026, an increase from $296.7 million in the prior year period, driven by higher net product sales. Despite the revenue growth, the company experienced a significant net loss of $73.9 million in the third quarter of 2026, primarily due to $139.5 million in negative fair value adjustments on equity and long-term investments.

Q3 2026 at a glance · $ million
MetricQ3 2026Q3 2025
Revenue106.1107.8
Gross profit84.475.5
Profit before tax-97.697.8
Net income-73.989.9
EPS (diluted, $ a share)$-1.03$1.08

A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.

Growth and margins
Revenue, year on year-1.6%
Gross margin79.5%
Operating margin39.7%
Source

10-Q filed with the SEC, NASDAQ: INVA. Figures from the filing's XBRL data; summary written with AI assistance from the filing.

Read the filing ↗

Innoviva, Inc.: key numbers

Share price
$18.49Close, Nov 16
Market cap
$1.31B
Shares outstanding
71.08MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from Innoviva, Inc.

All →
4:26 PM ET 8-K
Financial Results

Innoviva Financial Results

Innoviva reported third quarter 2026 financial results, featuring total revenue of $106.1 million and a 45% year-over-year increase in U.S. net product sales to $43.3 million. Despite strong operational income of $42.2 million, the company recorded a net loss of $73.9 million due to a $139.5 million unfavorable change in the fair value of its equity investments, primarily Armata Pharmaceuticals.

Counterparty
Glaxo Group Limited
Term
Q3 2026

“IST delivered another quarter of excellent growth, with U.S. net product sales increasing 45% year-over-year to $43.3 million, keeping us on track to achieve our 2026 guidance of at least $150 million in U.S. net product sales.”

Pavel Raifeld, Chief Executive Officer of Innoviva

“Our durable royalty portfolio, coupled with a strong balance sheet and IST’s expanding revenue base, provides a strong foundation for disciplined, value-accretive capital allocation.”

Pavel Raifeld, Chief Executive Officer of Innoviva

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.